There have been calls for caution when it comes to the use of Pfizer’s respiratory syncytial virus (RSV) vaccine in pregnant women, ahead of an FDA advisory committee meet
GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrat
The industry looks set to bring the first vaccine for RSV to market in the coming year. But, which companies are leading the race, and why it would mark an important development for global health?
GSK looks set to bring the first vaccine for respiratory syncytial virus (RSV) to market in the EU, after its Arexvy shot was recommended for approval by the EMA’s human m
AbbVie has carved out a niche for its migraine drug Qulipta in a competitive market, after claiming FDA approval for the product in the prevention of chronic migraine.
Johnson & Johnson has decided to bow out of the market for respiratory syncytial virus (RSV) vaccines, abandoning a late-stage development programme that would have be